Contou/Tuetitute/Collebourtius He	it (CTCII) Desire				
Name of CICU	nt (CICU) Regist	ration Form			
Steve Gleason Institute for Neuroscience					
The unit is proposed to be a:					
Center or Institute					
Collaborative Unit					
Director of Center/Institute LAST NAME FIRST	NAME	WSU ID #	E-MAIL		PHONE #
Frank Marco		11409737	marcos.frank	(@wsu.edu	509-368-6747
What is the desired unit email address to be use	ad (if different from a	hovo)?			303 300 07 17
andrea.lazarus@wsu.edu	eu (ii uiiieieiit iioiii a	bove):			
Is this a new or existing WSU Center/Institute?					
New					
Existing					
This C/I is a					
College level C/I					
✓ University level C/I					
Does this proposed unit have a current website	address?				
✓ Yes No					
Website URL (please update to reflect accurate	information):				
gleason.wsu.edu					
Where will the unit be administratively housed (e	.g., college(s), Office	of Research)			
Area/College/Campus 1 WASHINGTON ST UNIV-SPOKANE		Area/0	College/Campus 2		
Other participating areas/colleges/campuses (if COL AG HUMAN & NAT RES SCI COLLEGE OF ARTS AND SCIENCES COLLEGE OF ENG VOILAND COLLEGE OF NURSING ES FLOYD COLLEGE OF MEDICINE PHARMACY & PHARM SCIENCES VET MEDICINE COLLEGE OF WASHINGTON ST UNIV-VANCOUVER WASHINGTON ST UNIV-SPOKANE	applicable):				
What is the primary mission of the proposed u	nit?				
Research					
Teaching, Service, and/or Outreach					
Both (uncommon – neither research nor t	eaching/service outre	ach is primary but b	ooth are equally weig	hted)	
Preference for annual and five-year review due	dates (please choose	one):			
Annual report submission due August 1; f	ive-year review subm	ission due Novembe	er 1		
Annual report submission due December :	1; five-year review su	bmission due March	1		
Last 5-year Review Date (admin only)	month/day	ı/year 🛗		Save Reporting Date	
Mission statement, including specific goals (no r	more than a paragrap	h is expected):			
The mission of the Stephen Gleason Institute for education, caregiver support, clinical care, and research to transform our understanding and to clinical care for patients with neurodegenerative neurodegenerative diseases; (4) To create education interested in understanding neurodegenerative provide outreach and education about neurodegenerative	I clinical/pre-clinical bareatment of neurodegote diseases; (3) To descriptional and experience diseases and their in	rain research. The I generative diseases; velop innovative ada tial opportunities fo npact on caregivers	nstitute has five goal (2) To partner with a aptive technologies to r future generations and their families; a	s: (1) To promote collaborarea medical providers to enhance the quality of lift of scientists, clinicians, en	rative, interdisciplinary provide coordinated fe of patients with gineers and therapists
Brief description of major focus areas (100 word	ds or less is expected)):			
The Gleacon Institute has three integrated uni	ts (discovery adaptiv	e technologies and	clinical recearch) the	t build on WSII's extensive	a resources to develop

new technologies and treatments to improve the quality of life of those with neurodegenerative diseases and provide education and support for their

WSU and match clinical service providers with WSU faculty to help support clinical research and care. The Gleason Institute will also collaborate with

caregivers. The Institute will also create educational and educational opportunities for students and providers, serve as a hub for neuroscience research for

1/4

https://myresearch.wsu.edu/cicu/registration/60

community partners and patient organizations to identify needs and coordinate resources.

Keywords for major focus areas (list two to six):

neuroscience neurodegenerative amyotrophic lateral motor neuron caregiver adaptive technology

disease

Value added by creation of the unit (consider all aspects of a land-grant university mission - no more than a paragraph is expected):

sclerosis

The Gleason Institute embodies the land-grant mission of WSU by delivering education to the community and making the benefits of WSU research available to patients and providers by transforming knowledge into practice. Within WSU, the Gleason Institute will draw together researchers in different disciplines and colleges and act as an intellectual catalyst to develop new technologies, treatments, and care paradigms for people with neurodegenerative diseases. It will also serve as a bridge between researchers, providers, and patients to provide a holistic, patient-centered approach to treating patients with neurodegenerative disorders.

Associated members and their department/school affiliation:

Members (M) & Fellows (F):

Priyanka Bushana (M), Graduate Student, WSU College of Medicine, Department of Biomedical Sciences

Naomi Chaytor (F), Associate Professor, WSU College of Medicine, Department of Medical Education and Clinical Sciences

Gail Chermak (M), Professor and Chair, WSU College of Medicine, Department of Speech and Hearing Sciences

Diane J. Cook (M), Regents Professor & Huie-Rogers Chair, WSU, School of Electrical Engineering & Computer Science

Chris Davis (M), Clinical Associate Professor, WSU College of Medicine, Department of Biomedical Sciences

Jon F. Davis (M), Assistant Professor, WSU College of Veterinary Medicine, Integrative Physiology and Neuroscience

Travis Denton (F), Assistant Professor, WSU College of Pharmacy & Pharmaceutical Sciences, Department of Pharmaceutical Sciences

Marcos Frank (M), Professor & Chair, WSU College of Medicine, Department of Biomedical Sciences

Jason Gerstner (F), Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences Hassan Ghasemzadeh (M), Associate Professor, WSU, School of Electrical Engineering & Computer Science Chris Hayworth (M), Research Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences

Darrell Jackson (M), Clinical Assistant Professor, WSU College of Pharmace & Pharmaceutical Sciences, Department of Pharmaceutical Sciences Ashley Ingiosi (M), Post-Doctoral Fellow, WSU College of Medicine, Department of Biomedical Sciences

Josh Jacobs (M), Professor, WSU College of Medicine, Department of Medical Education and Clinical Sciences Dave Jenson (M), Assistant Professor, WSU College of Medicine, Department of Speech and Hearing Sciences Levente Kapàs (M), Associate Professor, WSU College of Medicine, Department of Biomedical Sciences

Jae Kennedy (M), Professor, WSU College of Medicine, Department of Medical Education and Clinical Sciences

Matt Layton (M), Director, Associate Dean, WSU College of Medicine, Department of Medical Education and Clinical Sciences

Andrea Lazarus (M), Professor, Associate Dean, WSU College of Pharmacy and Pharmaceutical Sciences

Yiyong (Ben) Liu (M), Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences

Ryan McLaughlin (M), Assistant Professor, WSU College of Veterinary Medicine, Integrative Physiology and Neuroscience

Christine Muheim (M), Post-Doctoral Fellow, WSU College of Medicine, Department of Biomedical Sciences Lucia Peixoto (M), Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences Beverly M. Rabbitts (M), Assistant Research Professor, WSU College of Veterinary Medicine, Integrative Physiology and Neuroscience

Maureen Schmitter-Edgecombe (M), Herbert L. Eastlick Distinguished Professor, WSU, Department of Psychology

Steve Simasko (M), Professor and Chair, WSU College of Veterinary Medicine, Integrative Physiology and Neuroscience

Astrid M. Suchy-Dicey (M), Assistant Research Professor WSU College of Medicine, Department of Medical Education and Clinical Sciences

Jingru Sun (M), Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences

Evà Szentirmai (M), Associate Professor, WSU College of Medicine, Department of Biomedical Sciences

Laurie Thompson (M), Assistant Professor, WSU College of Medicine, Department of Speech and Hearing Sciences

Mark Vandam (M), Associate Professor, WSU College of Medicine, Department of Speech and Hearing Sciences

William Vanderheyden (M), Research Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences

Phillip Wibisono (M), Graduate Student, WSU College of Medicine, Department of Biomedical Sciences

Jonathan Wisor (M), Professor, WSU College of Medicine, Department of Biomedical Sciences

Liz Wood (M), Assistant Professor, WSU College of Medicine, Department of Medical Education and Clinical Sciences

Criteria for membership:

All faculty that have an interest in neurodegenerative disease research, adaptive technologies, artificial intelligence, and other areas that are relevant to the mission of the Gleason Institute are welcome as members.

Does this CICU have an Advisory Board?



✓ Yes No

Please list Board members:

The Gleason Institute for Neuroscience is assisted by a steering committee as well as three advisory boards (scientific, clinical, and community) as well as a steering committee. Advisory boards meet quarterly, while the steering committee meets annually. Minutes and recommendations are prepared as reports for the Institute leadership.

Steering Committee: The Steering Committee provides overall advice and guidance to the Executive team. It is comprised of principle stakeholders and partners. The Steering Committee will be absorbed into the Advisory Boards once the GIN has been fully established.

Susan Ashe, Executive Director, Health Sciences and Services Authority

Greg Carter, Chief Medical Officer, St. Luke's Rehabilitation Institute

Daryll DeWald, Chancellor of WSU Spokane and Vice President for Health Sciences for WSU

Clare Durrett, Associate Executive Director, Team Gleason

Marcos Frank, Director of the Gleason Institute

Tony Hazel, Superior Court Judge. Department 6

Latisha Hill, Senior VP, Avista Development; Director of Community and Business Development

Andrea Lazarus, Executive Director of the Gleason Institute

Theresa Wild, Project Manager Gleason Institute, vice President/Communications Director, Matt's Place, Coeur d'Alene

Scientific Advisory Board: The Scientific Advisory Board advises on technology, pharmacology and neuroscience goals of the GIN. They also advise on partnerships with industry and local, state and federal opportunities for funding science in the Gleason Institute.

Craig Bakker, Director, Providence Spokane Neuroscience Institute

Jon Campbell, Research Software Development Engineer, Microsoft Research

Diane Cooke, Regents Professor & Huie-Rogers Chair of Electrical Engineering & Computer Science, WSU

)	20 WSU M
	Joe Harding, Professor, Integrative Physiology and Neuroscience, WSU David O'Brien, Senior Vice President and Chief Executive, MultiCare East Region Jason Minton, Network Engineer, WSU Spokane Steve Simasko, Chair, Integrative Physiology and Neuroscience, WSU Doug Weeks, Director of Research, St. Luke's Rehabilitative Institute
	Clinical Advisory Board: The Clinical Advisory Board advises on best care practic from current therapies, clinical trials, information services and outreach.
	John Demakas, Chief Medical Officer, MultiCare Neuroscience Institute

ctices and services for patient populations served by the GIN. This can range

Ken Isaacs, Director, Providence Spokane Neuroscience Institute

David O'Brien, Senior Vice President and Chief Executive, MultiCare East Region

Greg Carter, Chief Medical Officer, St. Luke's Rehabilitation Institute

Community Advisory Board: The Community Advisory Board includes representatives from local and state agencies and organizations serving the ALS community (and communities impacted by related neurodegenerative diseases), local stakeholders (businesses, mayor's office), WSU.

Nathan Zeigler, Executive Director, ALS Association, Evergreen Chapter Gail Gleason, WSU Athletics Debbie King, Founder, ALS Service Organization

Brandi Gore, ALS Patient Advocate

Lars Gilbert, Chief Executive Officer, Spokane University District

Are there external funding possibilities related to this CICU?



✓ Yes No

Please list (be as specific as possible, e.g., listing example RFAs):

The intent of the Gleason Institute is to stimulate research into motor neuron and other neurodegenerative diseases and bring together researchers across WSU to leverage and expand research interests. The ultimate goal of the Institute is to attract funding to support a Center of Excellence in this area. However, the Institute will also foster individual research applications to federal agencies and foundations. The Gleason Institute will also apply to foundations that provide funds for infrastructure, and has already been successful in attracting funding from the Christopher and Dana Reeve Foundation to build a wheelchair-accessible front entrance in the Sprague building that showcases the 'smart home' technologies available for those with neurodegenerative diseases. Other foundations that will be targeted include the Michael J Fox Foundation, National Ataxia Foundation, Lauzier Foundation, Multiple Sclerosis Foundation, Parkinson's Foundation, Promobilia Foundation, and Alzheimer's Drug Discovery Foundation. The Gleason Institute is also seeking in-kind donations of adaptive technologies from corporate donors such as Microsoft. The Gleason Institute may also partner with companies in SBIR and STTR proposals.

Does a similar unit exist within WSU?

Yes

No

Will the establishment of this unit impact the University Libraries beyond the impact already in place from the individual participating unit(s) (e.g., increased journal subscription needs)?

Yes

No

List specific metrics for evaluation and review (must be coordinated with goals and agreed upon by oversight authority/authorities; it is important that there be common themes to metrics across C/Is):

Success in achieving the goals of the Gleason Institute will be measured using the following metrics:

Research productivity:

- Number of grants submitted
- Number of external awards
- Number of collaborations between Gleason Institute members (eg, matching lab researchers with clinicians, engineers with patients, social scientists with patients and caregivers)
- Establishment of dedicated laboratory space and core facilities

Community outreach:

- Number of patients accessing the Smart Home Center in the Sprague building
- Number of partnerships with outside patient organizations
- Number of partnerships with technology companies
- Number of partnerships with clinical entities

Teaching:

- Number of patients seeking counsel and referrals
- Number of students involved in Gleason Institute activities

Please upload the most recent organization chart (include leadership structure, faculty, staff, and advisory units as applicable; be sure to include oversight authority/authorities):

Org Chart: Gleason Institute Organizational Chart.pdf

Budget overview, showing revenue (e.g., central funding, endowments, external funding, indirect cost recovery, projected income from service centers, tuition) and expenses (e.g., salaries, tuition, equipment purchase and upkeep, licenses, operational expenses, outreach activities), with evidence of approval at the appropriate level. If the C/I includes service centers, a description of services and revenue and expenses analysis

Budget Overview (Note: You cannot edit this without re-uploading a new file): Gleason Institute budget.pdf

Support letter(s) from proposed line(s) of authority (e.g., Dean, Chancellor, VPR, Provost). In addition to providing support and rationale for the overall establishment of the C/I, the oversight authority/authorities must address approval of the allocated budget, if applicable, in the support letter.

Support Letter: <u>DeWald LOS for GIN application.pdf</u>

Support Letter:

Support Letter:

Ву

;

Created Lazarus, Andrea on Oct 30, 2020,

11:48:12 AM

Last

By

Lazarus, Andrea on Oct 30, 2020,

Modified

11:48:12 AM

Oversight Authority/Authorities


Oversight Authority/Authorities Note: must be at the college Dean level or higher.

LAST NAME FIRST NAME WSU ID # E-MAIL

Dewald Daryll 9912338 daryll.dewald@wsu.edu

Make Editable

Gleason Institute for Neuroscience (GIN) Organizational Chart 2020



CRCU: Clinical Research and Care Unit; ATSH: Adaptive Technology and Smart Home Center; DRU: Discovery Research Unit

<u>Vice President for Health Sciences (Daryll DeWald):</u> The VP for Health Sciences decides a) the composition of the GIN executive team b) allocations of WSU and Campus resources in service of the Gleason Institute integration with Chancellor/VP broader strategic plans d) helps (where applicable) with each branch point of this organizational chart.

<u>Director (Marcos Frank):</u> The Director reports to the Chancellor/VP. He/she oversees overall planning and sets goals for the entire institute. The Director develops and approves the strategic plan. Changes in direction, partnerships, hiring, funding, investments, and other major organizational changes require Director approval. The Director delegates tasks to other members of the GIN organization. *The Director is the first contact for all inquiries about the GIN unless otherwise indicated.*

<u>Executive Director (Andrea Lazarus)</u>: The Executive Director reports to the Director. His/her duties include organizational and administrative tasks necessary to execute the Director's plans, short-term and long-term. More specifically, the executive director will ensure that WSU administrative tasks necessary to carry out the GIN strategic plans are executed in a timely fashion. Ultimately, all financial planning, fund raising and other mechanisms necessary to establish and sustain the institute financially are the Executive Director's responsibility.

<u>Project Manager (Theresa Whitlock-Wild):</u> The Project Manager reports to the Executive Director or the Director, as determined by the Director. He/she executes specific tasks for the GIN as decided in discussions with the Executive Director and Director. These tasks can change depending on "facts on the ground".

<u>Associate Directors:</u> Each GIN unit has an Associate Director. He/she is responsible for executing the mission of the respective unit. Associate Directors report directly to the GIN Director. They have broad authority to act to carry out the mission of their unit. Associate Directors will be named as the Gleason Institute expands. Until then, Marcos Frank will oversee the DRU, Theresa Whitlock-Wild will oversee the ATSH, and Doug Weeks at St. Luke's Rehabilitation Institute will oversee the CRCU.

Gleason Institute for Neuroscience Budget

The Gleason Institute was established with seed funding from Avista (\$250,000) and the Health Services and Sciences Authority of Spokane (HSSA; \$250,000). The funding from Avista was earmarked for the renovation of the Smart Home Center at 325 East Sprague Ave in Spokane, which was leased to the Gleason Institute for a period of three years for a nominal amount. These renovations should be completed by the end of 2020. A small gift from Microsoft was also received. The HSSA funding pays for operations costs for the start up of the Institute as detailed below:

		Expense
	Award	(through 9/1/2020)
HSSA Award	\$250,000	
Microsoft gift	\$18,500	
WSU Foundation		-\$15,000
Salaries		-\$67,250
Executive director (.25 FTE)		
Project manager (.50 FTE)		
Gleason Fellows (4)		-\$20,000
VCOE senior capstone project		-\$5000
Supplies		-\$100
Travel		-\$1250
Marketing		-\$50,000
Net remaining:	\$109,900	

When the Smart Home Center at 325 E. Sprague Blvd. opens, there will be a need for additional staffing that is expected to be financed through donations from donors and industry.

Office of the Vice President/Chancellor

October 7, 2020

Dear Members of the Review Group,

I would like to enthusiastically express my support for the application of the Steve Gleason Institute for Neuroscience to move from interim to established Institute status at Washington State University. The Gleason Institute was launched in January, 2019 with funding from the Avista Foundation and the Health Sciences and Services Authority (HSSA) of Spokane. The Avista Foundation also provided the Gleason Institute with a physical home at the south end of the University District Gateway Bridge on Sprague Avenue, with their portion of the seed funds going towards renovation of the building. The HSSA sponsorship has provided funds for the hiring of key personnel and initiation of Gleason Institute activities.

The Gleason Institute also has a robust relationship with Team Gleason, the nonprofit organization developed by Steve Gleason, the WSU alum and former NFL football player who was diagnosed with ALS in 2011 and for whom the Gleason Institute is named. Team Gleason has pledged to assist the Gleason Institute with fundraising initiatives, networking opportunities, and dissemination of Gleason Institute activities.

The Gleason Institute will be ready to occupy its renovated space in early 2021, and will offer a number of services to patients with neurodegenerative disease and their caregivers. The Gleason Institute itself has a tripartite mission: conducting foundational neuroscience research to identify new treatments and biomarkers for these conditions; developing and showcasing new adaptive technologies that improve quality of life and ease caregiver burden; and engaging in clinical research to evaluate new treatments and interventions for patients and their families. The Gleason Institute has partnered with Providence Health and Services and St. Luke's Rehabilitation Institute to deliver cutting-edge individualized clinical care to individuals with motor neuron disorders, and to offer them the opportunity to engage in clinical research studies. The Smart Home Center in the Sprague building will be the only facility of its kind that allows patients and their families the ability to not only learn about the technological resources available to them, but also the opportunity to try out these technologies for themselves in a home-like setting.

The establishment of the Gleason Institute confers a number of benefits on WSU. The Institute will bring together researchers engaging in neuroscience research across multiple colleges and be a hub for collaboration. Researchers from the Center of Advanced Studies in Adaptive Systems in the Voiland College of Engineering and Architecture have already partnered with the Gleason Institute on a number of initiatives, and the Gleason Institute has linked bioengineering students conducting capstone projects with patients and patient support

groups to develop new technologies to assist with everyday challenges. The Gleason Institute has also helped provide small seed grants to faculty to help kick off new research directions in new therapies for ALS and Alzheimer's, and the development of neurocognitive assessments for patients with motor neuron diseases. The Gleason Institute is also working together with regional start-up companies hoping to develop new adaptive technologies for patients with mobility and speech disabilities. It is hoped that the collaboration of researchers across disciplines will result in new external awards to reach our "Drive to 25" goals. Development activities will also be key to the success of the Gleason Institute.

As Vice President for Health Sciences and Chancellor of Health Sciences, I urge you to support the application moving the Steve Gleason Institute for Neuroscience from interim to established Institute status.

Sincerely,

Daryll B. DeWald, PhD

Vice President and Chancellor of Health Sciences

WSU Health Sciences Spokane

Dayl B. Oslevald

Name	Comment	Submitted
Halaas, Gwen W	I have reviewed this form and attachments and support the approval of the Steve Gleason Institution for Neuroscience. I have no further comments or concerns. Gwen Halaas, MD, MBA, Vice Chancellor for Academic Affairs, ,WSU Health Sciences	11/2/20, 2:09 PM
Barbosa-Leiker, Celestina	I support the approval of the Stephen Gleason Institute for Neurosciences as a formal WSU Institute.	11/2/20, 2:13 PM
Field, David P	This looks great to me. It's the first I've heard of this effort and I think they've done a nice job of developing the Institute. I'm all in favor of it.	11/2/20, 4:08 PM
Holder, Lawrence	Only 1 support letter. Otherwise looks good.	11/2/20, 4:23 PM
Gaffney, Michael John	I note that all of the identified evaluation metrics are output measures. This is probably appropriate and sensible for a start-up, but should evolve to assess both outcome measures and impacts as the Center's activities mature.	11/2/20, 5:11 PM
Buchwald, Dedra	This a very exciting proposal and will facilitate WSU's making a mark in the filed of neurodegenerative diseases. These application are quite short and do not allow enough space to describe many of the important infrastructural questionsso here are a few. Will there be any income from clinical services either directly offered or generated indirectly? Will F and A rate be 26% or standard on-site? Will the Institute generate IDC recovery for the unit? How will rent be covered in 2-3 years when the current nominal rent runs out? For awards (a metric for success), whose awards will be counted? All members? Only those that receive some predetermined type of support? How will the salaries for the current management team and eventually the added 3 directors be covered in the future? Can these administrative costs be put on grants? How much in grant funding is anticipated to be needed to fully support the Institute? Thank you	11/2/20, 7:07 PM
Beattie, Mark A	This Center will be a fine addition to our Land Grant mission in the state of Washington and beyond. What a tribute to Steve Gleason!	11/3/20, 9:13 AM
Postma, Julie Marie	The Gleason Center will be a valuable addition to WSU. Please list specific faculty members from the College of Nursing as associated members, in addition to listing the College.	11/3/20, 10:36 AM

Trevisan, Michael Steven	The overall mission seems on target. There is potential for real value added to the university and a broader societal contribution. I do have concern about the small start-up funding. Unless grant funding or donations of a reasonable size come soon, the unit work could be jeopardized.	11/3/20, 1:53 PM
Oatley, Jon Michael	The premise of the institute is logical given a critical mass of investigators in the field of neuroscience at WSU. However, I do have reservations about what the impact could be based on the descriptions provided. Like all institutes, strong executive leadership with a progressive vision and track-record of accomplishment in building large interdisciplinary programs is essential. Qualifications of the executive director for leading such a grand challenge of establishing a new institute are not well described. Based on a quick search for previous record of NIH funding and peer-reviewed publications, I am unable to find record of accomplishment for the proposed executive director in the broad field of neuroscience. Also, knowing what the director and executive director's previous accomplishments in establishing and leading institutes are would be useful information in assessing what the potential merit is for the proposed institute.	11/3/20, 2:52 PM
	Four different advisory boards and/or committees with membership ranging from 4-9 individuals have been listed, but their duties and roles are not described. It will be important to define what the purposes and charges are for the different entities in ensuring that the proposed institute is successful. There is a general lack of description about what the output metrics will be for evaluating and reviewing success. The research productivity metrics that have been described are rather ambiguous and should be expanded to set target points. In addition, metrics for scholarly outputs in the form of peer-reviewed publications, intellectual property and commercialization, etc. should be included. As described, gauging the impact of institute activities could be quite challenging.	

A sustainable budget is not in place, as best I can tell. Without this, I am not sure how an institute

could realistically be formed.

Mealey, Katrina Ann	Because neuroscience has been a WSU research strength for decades, establishing a Center or Institute was judicious. The involvement of a high-profile foundation founded by a home-town hero afflicted by a neurodegenerative disease increases the visibility of this Institute but also increases the expectations. It is imperative that the Gleason Institute produce impactful, tangible outcomes like therapeutic candidates or diagnostic tools, not simply a list of funded grants and publications. In order to achieve these outcomes, the Gleason Institute should (i) strive to include each and every active neuroscience researcher at WSU; (ii) hold quarterly (or at least annual) meetings of the scientific advisory committee; (iii) annually engage with leadership of colleges whose faculty are a part of the Gleason Institute. Because these are not happening the Gleason Institute is not likely to achieve its full potential. I would be happy to discuss this further.	11/5/20, 8:19 PM
Pietsch, Alexander Roy	I am extremely excited by the vision for the Gleason Institute and am supportive of its establishment. I believe it holds tremendous promise. However, I have concerns about the financial model and the long-term sustainability of the effort. The budget documents shared here provide little detail about how the Institute will operate on a day-to-day basis, let alone grow in to its potential. Corporate Relations is committed to helping bring industry partners to the table. In order to secure financial support from industry, we must be armed with more tangible information about what the Institute will do, what it can achieve, and how it will actually work. In summary, I am supportive of the Institute's formal	11/9/20, 3:54 PM

designation, but there is much work to be done to

ensure its viability.

From: Lazarus, Andrea <andrea.lazarus@wsu.edu>

Sent: Monday, November 30, 2020 10:44 PM To: Barry, Tammy <tammy.barry@wsu.edu> Cc: DeWald, Daryll B <daryll.dewald@wsu.edu>

Subject: Gleason Institute response to stakeholder comments

Dear Tammy,

Please see our attached response to the comments received as part of the Gleason Institute's application for approval as a formal institute. Our response has been reviewed and approved by Daryll DeWald, VP for Health Sciences, who has oversight authority for the Institute. If there are any remaining questions or concerns, please do not hesitate to contact me.

Thank you for help in this process,

Andrea

To: Research and Arts Committee

From: Marcos Frank, Director, Steve Gleason Institute for Neuroscience

Andrea Lazarus, Executive Director, Steve Gleason Institute for Neuroscience

November 30, 2020

Thank you for the helpful comments regarding the application of the Steve Gleason Institute for Neuroscience for formal institute status. We have provided additional clarification to address some of the concerns noted, and will be following up with individual stakeholders who offered constructive suggestions. Please feel free to contact us if there are any additional questions.

Qualifications of Steve Gleason Institute for Neuroscience Leadership

Director: The role of the Director is to provide overall direction and vision for the institute, develop partnerships with regional and federal agencies and organizations to promote the mission of the institute, and to work with stakeholders to sustain and build the institute. Marcos Frank received his BA in psychobiology at the University of California Santa Cruz and his PhD in neuroscience at Stanford University. He completed a post-doctoral position at the University of California San Francisco in the department of physiology. From 2003-2013, he was an assistant and then associate professor at the University of Pennsylvania Department of Neuroscience. He is a Professor and inaugural Chair (2014-2020) in the Department of Biomedical Sciences at Washington State University, in the Elson S. Floyd College of Medicine. His research interests include the cellular basis for sleep regulation in adult and developing animals and the role of sleep in synaptic plasticity, neurodegeneration and brain maturation.

Executive Director: The role of the Executive Director is to provide administrative oversight of the institute infrastructure, programs, and strategic planning, and act as primary contact for marketing, public relations, and fundraising initiatives. Andrea Lazarus received her BSc from McGill University in human genetics, an MS from Cornell University in cell biology and genetics, and a PhD in experimental medicine from McGill University. She has held a number of administrative positions in university-level centers and institutes, first at the Moffitt Cancer Center in Tampa, then as administrator of the Penn State Cancer Center, where she established a biobank and clinical research center. She was also instrumental in procuring a Clinical and Translational Science award at Penn State, and establishing the Penn State Clinical and Translational Science Institute, serving as administrator of the institute. At WSU, she is Associate Dean for Research in the College of Pharmacy and Pharmaceutical Sciences, and served as Assistant Vice President for Research, overseeing centers and institutes, from 2013-2019. Since 2019, she has been Associate Vice President for Health Sciences.

Project Manager: The role of the project manage is to manage individual projects within the Institute as determined by the Director, depending on priority. At present, the project manager is engaged in overseeing the completion of the Adaptive Technology and Smart Home Center located in the Sprague building. Theresa Whitlock Wild completed her BA in Communications at Lewis-Clark State College and her MA in Organizational Leadership from Gonzaga University. She is the co-founder of Matt's Place Foundation, a non-profit organization that provides people with ALS and their families with the resources they need for remaining in their homes while battling this neurodegenerative disease and providing funding for remodeling homes. Matt's Place has also built one home and is in the process of building another that provides temporary housing with all the necessary smart home technologies for those with ALS and their families.

Updated list of members and their department/school affiliation:

Members (M) & Fellows (F):

Lindsay Azchet (M), Graduate Student, Pharmaceutical Sciences

Priyanka Bushana (M), Graduate Student, WSU College of Medicine, Department of Biomedical Sciences **Greg Carter (F),** Chief Medical Officer, St. Luke's Rehabilitation Institute

Naomi Chaytor (F), Associate Professor, WSU College of Medicine, Department of Medical Education and Clinical Sciences

Chia-Hui Chen (M), Graduate Student, Pharmaceutical Sciences

Gail Chermak (M), Professor and Chair, WSU College of Medicine, Department of Speech and Hearing Sciences

Diane J. Cook (M), Regents Professor & Huie-Rogers Chair, WSU, School of Electrical Engineering & Computer Science

Chris Davis (M), Clinical Associate Professor, WSU College of Medicine, Department of Biomedical Sciences

Jon F. Davis (M), Assistant Professor, WSU College of Veterinary Medicine, Integrative Physiology and Neuroscience

Travis Denton (F), Assistant Professor, WSU College of Pharmacy & Pharmaceutical Sciences, Department of Pharmaceutical Sciences

Marcos Frank (M), Professor & Chair, WSU College of Medicine, Department of Biomedical Sciences Jason Gerstner (F), Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences Hassan Ghasemzadeh (M), Associate Professor, WSU, School of Electrical Engineering & Computer Science

Chris Hayworth (M), Research Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences

Darrell Jackson (M), Clinical Assistant Professor, WSU College of Pharmacy & Pharmaceutical Sciences, Department of Pharmaceutical Sciences

Ashley Ingiosi (M), Post-Doctoral Fellow, WSU College of Medicine, Department of Biomedical Sciences **Josh Jacobs (M),** Professor, WSU College of Medicine, Department of Medical Education and Clinical Sciences

Dave Jenson (M), Assistant Professor, WSU College of Medicine, Department of Speech and Hearing Sciences

Levente Kapàs (M), Associate Professor, WSU College of Medicine, Department of Biomedical Sciences **Jae Kennedy (M),** Professor, WSU College of Medicine, Department of Medical Education and Clinical Sciences

Matt Layton (M), Director, Associate Dean, WSU College of Medicine, Department of Medical Education and Clinical Sciences

Andrea Lazarus (M), Professor, Associate Dean, WSU College of Pharmacy and Pharmaceutical Sciences Yiyong (Ben) Liu (M), Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences Ryan McLaughlin (M), Assistant Professor, WSU College of Veterinary Medicine, Integrative Physiology and Neuroscience

Christine Muheim (M), Post-Doctoral Fellow, WSU College of Medicine, Department of Biomedical Sciences

Lonnie Nelson (M), Associate Professor, WSU College of Nursing

Lucia Peixoto (M), Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences **Beverly M. Rabbitts (M),** Assistant Research Professor, WSU College of Veterinary Medicine, Integrative Physiology and Neuroscience

Maureen Schmitter-Edgecombe (M), Herbert L. Eastlick Distinguished Professor, WSU, Department of Psychology

Steve Simasko (M), Professor and Chair, WSU College of Veterinary Medicine, Integrative Physiology and Neuroscience

Astrid M. Suchy-Dicey (M), Assistant Research Professor WSU College of Medicine, Department of Medical Education and Clinical Sciences

Jingru Sun (M), Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences Evà Szentirmai (M), Associate Professor, WSU College of Medicine, Department of Biomedical Sciences Laurie Thompson (M), Assistant Professor, WSU College of Medicine, Department of Speech and Hearing Sciences

Catherine Van Son (M), Associate Professor, WSU College of Nursing

Mark Vandam (M), Associate Professor, WSU College of Medicine, Department of Speech and Hearing Sciences

William Vanderheyden (M), Research Assistant Professor, WSU College of Medicine, Department of Biomedical Sciences

Phillip Wibisono (M), Graduate Student, Pharmaceutical Sciences

Jonathan Wisor (M), Professor, WSU College of Medicine, Department of Biomedical Sciences **Liz Wood (M),** Assistant Professor, WSU College of Medicine, Department of Medical Education and Clinical Sciences

Clarification of budget:

The Clinical Research and Care Unit is based at St. Luke's Rehabilitation Institute, and all clinical services are delivered there. There is no impact on the overall Gleason Institute budget based on the clinical activities, and St. Luke's/Providence is responsible for all expenses and billing of services, and will retain all revenue from clinical care services.

The Discovery Research Unit is composed of the faculty, staff, and students currently engaging in neuroscience research throughout WSU. At this time, there are no expenses associated with the DRU, and no income accruing from these activities. As the Gleason Institute expands and institute members begin submitting collaborative grants through the institute, it is hoped that an indirect cost recovery model can be developed whereby a portion of the indirect costs associated with these grant can be returned to the Gleason Institute to help fund infrastructure expenses.

The Adaptive Technologies and Smart Home Center is the focus of current fundraising efforts. As discussed in our budget statement, the Avista Foundation provided a 3-year lease on the Sprague building at a nominal cost and donated \$250,000 to help renovate the space. The Health Sciences and Services Authority of Spokane (HSSA) provided an additional \$250,000 for operating costs. The decision to focus on building up this space as one of the first activities of the Gleason Institute is three-fold: 1) Team Gleason, as a major partner with the Gleason Institute, is primarily interested in developing and distributing technologies that will improve the quality of life of those with neurodegenerative diseases; 2) our community partners have a stake in seeing the Sprague building serve as a focal point for developing this area of Spokane as a biomedical hub; and 3) having a Smart Home Center where patients with neurodegenerative diseases can view, test, and help develop new technologies will help distinguish the Gleason Institute for Neuroscience from other academic neuroscience institutes. However, funding to outfit the Smart Home Center and provided services there (which are not billable to insurance companies) will be provided by WSU Health Sciences, philanthropy and by partnering with companies that develop these assistive technologies.

RAC Checklist for Establishing a New Center/Institute

Gleason Institute Name of Center/Institute:

Director of Center/Institute: Marcos Frank and Andrea Lazarus

Oversight Authority/Authorities:

Daryll DeWald

Reviewer from RAC: Tammy Barry

Criterion:	Criterion Met:	Notes:
Request form to establish a C/I completed	• Yes • No	Date received: 10/30/20
Request form reviewed and approved by all oversight authorities with approval letter(s)	• Yes No	
Cleary identifies oversight authority, which appears appropriate given the proposal	• Yes No	Daryll DeWald
Includes organization chart	• Yes No	
Includes detailed budget or statement that no resources are needed	• Yes No	
No apparent significant duplication with existing C/Is, per RAC review	• Yes No	
Sent to stakeholders for review and comment	• Yes No	Date sent: 11/2/20
Stakeholder comments sent to C/I director and response received	• Yes No	Date sent: 11/17/20
No comments in 10 business days or comments are addressed	• Yes No	
If applicable, any issues raised by the Library Committee are resolved	Oyes O No ONA	
If applicable, any issues noted by RAC are addressed	Yes No NA	See Notes below

Notes:

Given the limited scope provided for a long-term budget, rhe RAC noted that it will be important for the sustainability of the structure of the institute to be addressed in a future annual report to maintain communication with the oversight authority.

Approved by RAC and sent of Faculty Senate on 12/2/20 as a Discussion item (for eventual vote).

Attach additional page(s) as needed to provide any suggestions for potential coordination among C/Is or any feedback toward improvement.

RAC Checklist for Establishing a New Center/Institute

Gleason Institute Name of Center/Institute:

Director of Center/Institute: Marcos Frank and Andrea Lazarus Oversight Authority/Authorities:

Darryll DeWald

Reviewer from RAC: Kawkab Shishani

Criterion:	Criterion Met:	Notes:
Request form to establish a C/I completed	• Yes • No	Date received: 10/30/20
Request form reviewed and approved by all oversight authorities with approval letter(s)	• Yes No	
Cleary identifies oversight authority, which appears appropriate given the proposal	Yes No	
Includes organization chart	• Yes No	
Includes detailed budget or statement that no resources are needed	• Yes No	
No apparent significant duplication with existing C/Is, per RAC review	• Yes No	
Sent to stakeholders for review and comment	• Yes No	Date sent: 11/2/20
Stakeholder comments sent to C/I director and response received	• Yes No	Date sent: 11/30/20
No comments in 10 business days or comments are addressed	• Yes No	
If applicable, any issues raised by the Library Committee are resolved	Yes No NA	
If applicable, any issues noted by RAC are addressed	•Yes •No •NA	

N	otes	•
IΝ	OLCS	٠

Approved by RAC and sent of Faculty Senate on 12/2/20 as a Discussion item (for eventual vote).

Attach additional page(s) as needed to provide any suggestions for potential coordination among C/Is or any feedback toward improvement.